Article Type
Changed
Thu, 03/28/2019 - 09:12

 

Ezetimibe is found to be effective in lowering LDL for primary cardiovascular prevention in patients who were 75 or older. Also today, the FDA says that the benefits of paclitaxel-coated devices outweigh risks for peripheral arterial disease, flu activity is down for the second consecutive week, and a look at homelessness among LGBT youth in the United States.

Amazon Alexa

Apple Podcasts

Google Podcasts

Spotify

 

Publications
Topics
Sections

 

Ezetimibe is found to be effective in lowering LDL for primary cardiovascular prevention in patients who were 75 or older. Also today, the FDA says that the benefits of paclitaxel-coated devices outweigh risks for peripheral arterial disease, flu activity is down for the second consecutive week, and a look at homelessness among LGBT youth in the United States.

Amazon Alexa

Apple Podcasts

Google Podcasts

Spotify

 

 

Ezetimibe is found to be effective in lowering LDL for primary cardiovascular prevention in patients who were 75 or older. Also today, the FDA says that the benefits of paclitaxel-coated devices outweigh risks for peripheral arterial disease, flu activity is down for the second consecutive week, and a look at homelessness among LGBT youth in the United States.

Amazon Alexa

Apple Podcasts

Google Podcasts

Spotify

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica